

# MIRIKIZUMAB IMPROVES QUALITY OF LIFE IN PATIENTS WITH CROHN'S DISEASE UP TO 2 YEARS OF TREATMENT: RESULTS FROM THE VIVID-2 STUDY

Lisa Malter

UEG Week Berlin 2025

Poster

IBD

October 6, 2025

**Long-term quality of life outcomes from the VIVID-2 open-label extension study show sustained improvement through 2 years of mirikizumab treatment in patients with Crohn's disease.**

## KEY POINTS

- At week 104, endoscopic responders from VIVID-1 maintained IBDQ response at 85.0% and IBDQ remission at 71.3%, while endoscopic non-responders maintained IBDQ response at 72.6% and remission at 60.8%.
- Mean change from baseline in IBDQ total score was maintained through week 104 for endoscopic responders (57.2 points) and non-responders (46.8 points).
- EQ-5D-5L Visual Analog Scale scores improved at week 64 for both endoscopic responders (27.0 points) and non-responders (22.3 points).
- Work productivity and activity impairment measures showed improvements ranging from  $\square$ 13.9 to  $\square$ 34.3 across different WPAI:CD scores at week 64 in both groups.
- This material is most relevant for gastroenterologists evaluating long-term patient-reported outcomes and quality of life data for mirikizumab in moderate-to-severe Crohn's disease.

VIEW THIS CONTENT ON GUTFLIX

<https://gutflrx.eu/search/d/c85553c2-a813-11f0-b356-0242ac140006>



**AI-generated summary**

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.